# EDGAR Filing Document

**Accession Number:** 0001560241
**File Stem:** 0001562180-23-002911
**Filing Date:** 2023-3
**Character Count:** 9980
**Document Hash:** b01a8c9a2573cc1fedf9a8aa0dbf8b00
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001562180-23-002911.hdr.sgml**: 20230317

**ACCESSION NUMBER**: 0001562180-23-002911

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230315

**FILED AS OF DATE**: 20230317

**DATE AS OF CHANGE**: 20230317

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Umstead John V.
- **CENTRAL INDEX KEY:** 0001967910

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38096
- **FILM NUMBER:** 23742656

**MAIL ADDRESS:**
- **STREET 1:** C/O G1 THERAPEUTICS, INC.
- **STREET 2:** 700 PARK OFFICES DRIVE, SUITE 200
- **CITY:** RESEARCH TRIANGLE PARK
- **STATE:** NC
- **ZIP:** 27709
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** G1 Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001560241
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 263648180
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 700 PARK OFFICES DRIVE
- **STREET 2:** SUITE 200
- **CITY:** RESEARCH TRIANGLE PARK
- **STATE:** NC
- **ZIP:** 27709
- **BUSINESS PHONE:** 919-213-9835

**MAIL ADDRESS:**
- **STREET 1:** 700 PARK OFFICES DRIVE
- **STREET 2:** SUITE 200
- **CITY:** RESEARCH TRIANGLE PARK
- **STATE:** NC
- **ZIP:** 27709

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** G-Zero Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20121012

## Ex-24

```

POWER OF ATTORNEY
     Know all by these present, that the undersigned hereby
constitutes and appoints each of James Stillman Hanson, General
Counsel, of G1 Therapeutics, Inc. (the "Company"), Sandi James,
Director, Legal, of the Company, and Jason McCaffrey, Raven Sun,
Justin Omalev, Charles Smith, Tanya Sylla, and Brenda Meyette of
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly,
with full power of substitution, the undersigned's true and lawful
attorney-in-fact to:
(1)	execute for and on behalf of the undersigned, forms and
authentication documents for EDGAR Filing Access;
(2)	do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to
complete and execute any such forms and authentication
documents;
(3)	execute for and on behalf of the undersigned, in the
undersigned's capacity as an officer, director and/or 10%
shareholder of the Company, Forms 3, 4 and 5 in accordance
with Section 16(a) of the Securities Exchange Act of 1934
and the rules thereunder;
(4)	do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to
complete and execute any such Form 3, 4 or 5 and timely
file such form with the United States Securities and
Exchange Commission and any stock exchange or similar
authority; and
(5)	take any other action of any type whatsoever in connection
with the foregoing which, in the opinion of such attorney-
in-fact, may be of benefit to, in the best interests of,
or legally required by the undersigned, it being
understood that the documents executed by such attorney-
in-fact on behalf of the undersigned pursuant to this
Power of Attorney shall be in such form and shall contain
such terms and conditions as such attorney-in-fact may
approve in such attorney-in-fact's discretion.
     The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform any and every act and thing
whatsoever requisite, necessary, or proper to be done in the
exercise of any of the rights and powers herein granted, as fully to
all intents and purposes as the undersigned might or could do if
personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or
such attorney-in-fact's substitute or substitutes, shall lawfully do
or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges that
the foregoing attorneys-in-fact, in serving in such capacity at the
request of the undersigned, are not assuming, nor is the Company
assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934, as amended.
     This Power of Attorney shall remain in full force and effect
until the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the
undersigned in a signed writing delivered to the foregoing attorneys-
in-fact.
     IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed on February 28, 2023.
/s/ John Umstead V
	Signature

John Umstead V
	Print Name

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Umstead John V.<br><sub>(Last) (First) (Middle)</sub><br>700 PARK OFFICES DRIVE, SUITE 200<br><sub>(Street)</sub><br>RESEARCH TRIANGLE PARK, NC 27709<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>G1 Therapeutics, Inc. [ GTHX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-03-15 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Financial Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 8886.00<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Options (Right to buy) | 2022-10-22 | 2028-11-01 | Common Stock | 10000.00 | $41.48 | D |  |
| Stock Options (Right to buy) | <sup>(2)</sup> | 2029-07-01 | Common Stock | 2000.00 | $30.46 | D |  |
| Stock Options (Right to buy) | <sup>(3)</sup> | 2030-02-06 | Common Stock | 6600.00 | $21.08 | D |  |
| Stock Options (Right to buy) | <sup>(4)</sup> | 2031-01-04 | Common Stock | 2550.00 | $18.07 | D |  |
| Stock Options (Right to buy) | <sup>(5)</sup> | 2032-01-03 | Common Stock | 6100.00 | $10.69 | D |  |
| Stock Options (Right to buy) | <sup>(6)</sup> | 2033-01-03 | Common Stock | 6000.00 | $5.73 | D |  |

---

### Footnotes:

(1) Represents (i) 2,036 shares of common stock; (ii) 850 restricted stock units ("RSUs") from award granted on January 4, 2021; (iii) 3,000 RSUs from award granted on January 3, 2022; and (iv) 3,000 RSUs from award granted on January 3, 2023.

(2) The shares underlying this option vest as to 25% of the shares on July 1, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.  The option was granted on July 1, 2019.

(3) The shares underlying this option vest as to 25% of the shares on February 6, 2021, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.  The option was granted on February 6, 2020.

(4) The shares underlying this option vest as to 25% of the shares on January 4, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.  The option was granted on January 4, 2021.

(5) The shares underlying this option vest as to 25% of the shares on January 3, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.  The option was granted on January 3, 2022.

(6) The shares underlying this option vest as to 25% of the shares on January 3, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.  The option was granted on January 3, 2023.

**Signature:** /s/ James Stillman Hanson, attorney-in-fact  
**Date:** 2023-03-17

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**